Abstract Number: 0138 • ACR Convergence 2021
Treatment with Adalimumab in Patients with Chronic Inflammatory Rheumatic Diseases: A Study of Treatment Trajectories on a Patient Level in Clinical Practice
Background/Purpose: Adalimumab (ADA) retention rates are impaired in patients (pts.) with chronic inflammatory rheumatic diseases (CIRD) due to loss of efficacy and adverse events, causing…Abstract Number: 0813 • ACR Convergence 2021
Improvement in Clinical Disease Activity and Patient-Reported Outcomes After 6 Months of Treatment with Abatacept, Stratified by Line of Therapy, in Patients with RA: Results from a Large, US, National Observational Study
Background/Purpose: RA is more responsive to treatment in the early stages of disease, and early treatment may lead to better long-term outcomes.1,2 Data on the…Abstract Number: 1215 • ACR Convergence 2021
Development of a Multivariable Prediction Model for Treatment Response to Etanercept in a Multi-centre Cohort of Patients with Established RA
Background/Purpose: RA patients who respond inadequately to first-line DMARDs usually progress to a biologic DMARD. Treatment response to both DMARDs and biologics is heterogeneous within…Abstract Number: 1339 • ACR Convergence 2021
Treatment Persistence Was Similar at 3 Years in Patients with Psoriatic Arthritis Treated with Ustekinumab (STELARA®) or a Tumor Necrosis Factor Inhibitor in a Prospective Real-World Study
Background/Purpose: Several options exist in the treatment of PsA, but data on long-term persistence are rare. Here, we assess long-term persistence with ustekinumab (UST) or…Abstract Number: 1542 • ACR Convergence 2021
Does Adjustment to Dosing and Timing of Immunomodulatory Drugs Impact Immunogenicity of COVID19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Disease (AIIRD)?
Background/Purpose: Clinical trials leading to approval of the COVID19 vaccines did not include immunocompromised individuals. Concerns have been raised that immunogenicity of the vaccines may…Abstract Number: 1742 • ACR Convergence 2021
Efficacy of Anifrolumab in Serological Subgroups of Patients with SLE Participating in 2 Phase 3 Trials
Background/Purpose: In the TULIP-2 and TULIP-1 trials of patients with SLE, the type I IFN receptor mAb anifrolumab resulted in higher BILAG–based Composite Lupus Assessment…Abstract Number: 1885 • ACR Convergence 2021
Biological Therapy in Refractory Neurobehçet’s Disease. Multicenter Study of 42 Patients
Background/Purpose: Neurobehçet’s disease (NBD) is a severe complication of Behcet's disease (BD). Despite well-established therapies, with glucocorticoids and conventional immunosuppressants (cIS) a significant proportion of…Abstract Number: 0139 • ACR Convergence 2021
Treatment of Ankylosing Spondylitis by Primary Care Physicians and Rheumatologists in an Academic Health System: A Retrospective Study
Background/Purpose: While recommendations for the treatment of ankylosing spondylitis (AS) are largely aligned across various guidelines,1,2 there remains variability in the treatment. Patients with inflammatory…Abstract Number: 0825 • ACR Convergence 2021
An Investigator-initiated Multicenter Randomized Study in Early Rheumatoid Arthritis of Active Conventional Therapy versus Three Biological Treatments: 48 Week Clinical and Radiographic Results of the NORD-STAR Trial
Background/Purpose: The optimal first-line treatment of patients (pts) with early rheumatoid arthritis (eRA) is yet to be established. The main objectives were to assess and…Abstract Number: 1222 • ACR Convergence 2021
Drug Response Is Associated with Changes in Specific MicroRNAs in Patients with Rheumatoid Arthritis
Background/Purpose: MicroRNAs are markers and mediators of disease and drug response. Prior studies have proposed several miRNAs for prediction of drug response or monitoring drug…Abstract Number: 1341 • ACR Convergence 2021
Ixekizumab Shows a Pattern of Pain Improvement in Patients with and Without Measurable Inflammation in Psoriatic Arthritis
Background/Purpose: The efficacy of ixekizumab (IXE) and adalimumab (ADA) in patients with psoriatic arthritis (PsA) has been previously reported using ACR 50 and Psoriasis Area…Abstract Number: 1553 • ACR Convergence 2021
Low-dose Tocilizumab in the Treatment of COVID-19 Pneumonitis: 90-day Mortality Follow-up
Background/Purpose: Tocilizumab (TCZ) for treatment of severe coronavirus disease 2019 (COVID-19) pneumonia decreases the probability of progression to invasive mechanical ventilation (CORIMUNO-TOCI) or death (REMAP-CAP,…Abstract Number: 1750 • ACR Convergence 2021
Itolizumab, a Novel anti-CD6 Therapy, in Systemic Lupus Erythematosus Patients: Interim Safety Results from the Phase 1b EQUALISE Dose-escalation Study
Background/Purpose: CD6, a co-stimulatory receptor predominantly expressed on T cells, promotes CD4+ T cell proliferation and differentiation into Th1/Th17 cells. The CD6 ligand, activated leukocyte…Abstract Number: 1911 • ACR Convergence 2021
Patient’s and Rheumatologist’s Perspectives on the Burden of Adverse Drug Reactions Attributed to Biologics: A Qualitative Study
Background/Purpose: Previous studies showed a discrepancy between patient’s and HealthCare Professional (HCP) perspective on the burden of Adverse Drug Reactions (ADRs), where HCPs often underestimate…Abstract Number: 0184 • ACR Convergence 2021
Phase III, Randomized Trial Comparing Clinical Outcomes Between Patients with Moderate-to-severe Chronic Plaque Psoriasis Receiving Adalimumab Reference Product (RP) Continuously versus Those Who Switched Between BI 695501 and Adalimumab RP
Background/Purpose: BI 695501 is a FDA-approved biosimilar to adalimumab RP (AbbVie), and is approved in seven indications, including rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis,…
- « Previous Page
- 1
- …
- 39
- 40
- 41
- 42
- 43
- …
- 54
- Next Page »